Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (2020)	3/17/1999 3:00:00 PM
From: BMcV	Read Replies (1) \| Respond to of 10280

there's this too: "03/17 13:38 Lilly <LLY.N> Prozac estimate cut by Cowen-sources CHICAGO, March 17 (Reuters) - Shares of Eli Lilly and Co. fell 4-9/16 to 89-1/2 on Wednesday after market sources said a research firm cut its 1999 sales estimates for the drug company's flagship antidepressant Prozac, pressuring its earnings estimate. Lilly was not available for comment. Market sources said SG Cowen said in a written report that 1999 sales of Prozac could be significantly below Cowen's estimate, after Lilly made a presentation at a Cowen conference. Cowen analysts were also not available. Cowen said 1999 Prozac sales could be about $2.925 billion, up 4 percent from 1998 but below Cowen's previously published estimate of $3.050 billion, sources said. The reduced estimate was due to share lost to Forest Laboratories Inc.'s <FRX.A> Celexa and higher-than-normal trade stock levels at the start of 1999. Forest launched Celexa in September. According to the sources, Cowen reported that in Lilly's presentation, Lilly had said it was comfortable with a 1999 earnings per share range of $2.25 to $2.30, suggesting Cowen's $2.32 EPS estimate could be a couple of pennies high. Sources said the report said Cowen's 1999 sales estimate for Lilly's schizophrenia drug Zyprexa remains at $2.15 billion, but said the estimate was aggressive. Cowen noted that Lilly is defending Prozac sales with a more aggressive promotion plan and additional sales representatives, as well as new indications and formulations, the sources said." ______________________ But we all know the real reason for the drop: Hey, Bob, next time give us warning before you scoop up a bunch of calls! Happy St Paddy's Day All

To: Don Miller who wrote (2020)	3/17/1999 5:02:00 PM
From: M. Ramle	Read Replies (2) \| Respond to of 10280

Don: I have e-mailed the SEC at least twice in the last 6 months complaining about this manipulation by the MM's, but unfortunately there was no response. Boy, I thought I had some pull with the SEC !!! If you had noticed today, the spread at times was as wide as $2 1/4 which is a rip-off. All day, I was trying to buy some but failed to meet the MM's Asking Price. I will most certainly try tomorrow. Right at the close, I noticed that the Bid Price for the April 135 Puts dropped from $11 3/4 down to $11 1/8, which could be a sign of a large order on the buy-side. Mazen